COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,280 Articles (22,759 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 1994: Articles 19931-19940  | Next

Factors associated with clinical severity in Emergency Department patients presenting with symptomatic SARS-CoV-2 infection.
Newton, S., Zollinger, B., Freeman, J., Moran, S., Helfand, A., Authelet, K., McHarg, M., Montano Vargas, N., Shesser, R., Cohen, J., Cummings, D. A. T., Ma, Y., Meltzer, A. C.
10.1101/2020.12.08.20246017 — Posted: 2020-12-11
Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation analysis
Kiang, M. V., Chin, E. T., Huynh, B. Q., Chapman, L. A. C., Rodriguez-Barraquer, I., Greenhouse, B., Rutherford, G. W., Bibbins-Domingo, K., Havlir, D., Basu, S., Lo, N. C.
10.1101/2020.12.08.20246132 — Posted: 2020-12-11
How detection ranges and usage stops impact digital contact tracing effectiveness for COVID-19
Pandl, K. D., Thiebes, S., Schmidt-Kraepelin, M., Sunyaev, A.
10.1101/2020.12.08.20246140 — Posted: 2020-12-11
Neurological Disorders associated with COVID-19 Hospital Admissions : Experience of a Single Tertiary Healthcare Centre
Dhillon, P. S., Dineen, R., Morris, H., Tanasescu, R., Nikfekr, E., Evans, J., Constantinescu, C. S., Hosseini, A. A.
10.1101/2020.11.22.20235184 — Posted: 2020-12-11
Effects of photobiomodulation therapy combined with static magnetic field (PBMT-sMF) in patients with severe COVID-19 requiring intubation: a pragmatic randomized placebo-controlled trial
De Marchi, T., Francio, F., Ferlito, J. V., Weigert, R. M., de Oliveira, C. A., Merlo, A. P., Pandini, D. L., Pasqual Junior, B. A., Giovanella, D. F., Tomazoni, S. S., Leal-Junior, E. C. P.
10.1101/2020.12.02.20237974 — Posted: 2020-12-11
Intention of health care workers to accept COVID-19 vaccination and related factors: a systematic review and meta-analysis
Galanis, P. A., Vraka, I., Fragkou, D., Bilali, A., Kaitelidou, D.
10.1101/2020.12.08.20246041 — Posted: 2020-12-11
Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
Mishra, N., Kumar, S., Singh, S., Bansal, T., Jain, N., Saluja, S., Palanichamy, J. K., Mir, R. A., Sinha, S., Luthra, K.
10.1101/2020.12.09.418806 — Posted: 2020-12-10
SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential
Vithani, N., Ward, M. D., Zimmerman, M. I., Novak, B., Borowsky, J. H., Singh, S., Bowman, G. R.
10.1101/2020.12.10.420109 — Posted: 2020-12-10
Coiled-coil heterodimers with increased stability for cellular regulation and sensing SARS-CoV-2 spike protein-mediated cell fusion
Plaper, T., Aupic, J., Dekleva, P., Lapenta, F., Mancek, M., Jerala, R., Bencina, M.
10.1101/2020.12.10.419440 — Posted: 2020-12-10
An interactive viral genome evolution network analysis system enabling rapid large-scale molecular tracing of SARS-CoV-2
Ling, Y., Cao, R., Qian, J., Li, J., Zhou, H., Yuan, L., Wang, Z., Zheng, G., Zhao, G., Li, Y., Wang, Z., Zhang, G.
10.1101/2020.12.09.417121 — Posted: 2020-12-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).